ANIX (Anixa Biosciences) Shiller PE Ratio: (As of Sep. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ANIX Anixa Biosciences Inc ANIX
31 GF Score
Price $2.85
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anixa Biosciences  (NAS:ANIX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Anixa Biosciences Shiller PE Ratio Related Terms


Anixa Biosciences Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Shiller PE Ratio Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anixa Biosciences Quarterly Data
Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26 Jul26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANIX vs GNLX, PMN, NTHI: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Anixa Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Shiller PE Ratio falls into.


ANIX
31GF Score
Anixa Biosciences Inc ANIX
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Anixa Biosciences's E10 for the quarter that ended in Jul. 2026 is calculated as:

For example, Anixa Biosciences's adjusted earnings per share data for the three months ended in Jul. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jul. 2026 (Change)*Current CPI (Jul. 2026)
=-0.08/333.9180*333.9180
=-0.080

Current CPI (Jul. 2026) = 333.9180.

Anixa Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201610 -0.120 241.729 -0.166
201701 -0.410 242.839 -0.564
201704 0.020 244.524 0.027
201707 -0.120 244.786 -0.164
201710 -0.110 246.663 -0.149
201801 -0.110 247.867 -0.148
201804 -0.080 250.546 -0.107
201807 -0.300 252.006 -0.398
201810 -0.290 252.885 -0.383
201901 -0.250 251.712 -0.332
201904 -0.130 255.548 -0.170
201907 -0.110 256.571 -0.143
201910 -0.100 257.346 -0.130
202001 -0.130 257.971 -0.168
202004 -0.120 256.389 -0.156
202007 -0.110 259.101 -0.142
202010 -0.090 260.388 -0.115
202101 -0.090 261.582 -0.115
202104 -0.080 267.054 -0.100
202107 -0.140 273.003 -0.171
202110 -0.130 276.589 -0.157
202201 -0.130 281.148 -0.154
202204 -0.120 289.109 -0.139
202207 -0.090 296.276 -0.101
202210 -0.120 298.012 -0.134
202301 -0.080 299.170 -0.089
202304 -0.070 303.363 -0.077
202307 -0.080 305.691 -0.087
202310 -0.090 307.671 -0.098
202401 -0.100 308.417 -0.108
202404 -0.100 313.548 -0.106
202407 -0.100 314.540 -0.106
202410 -0.090 315.664 -0.095
202501 -0.100 317.671 -0.105
202504 -0.090 320.795 -0.094
202507 -0.070 323.048 -0.072
202510 -0.090 0.000
202601 -0.080 325.252 -0.082
202604 -0.070 333.020 -0.070
202607 -0.080 333.918 -0.080

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
31GF Score

Get the complete analysis for ANIX

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.85
Price